Drug intelligence / Profile preview

fotagliptin

Development stage: Phase 3
Lead developer: Shenzhen Salubris Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Fotagliptin (as fotagliptin benzoate) is a selective, once-daily, oral small molecule dipeptidyl peptidase-4 (DPP-4) inhibitor developed by Shenzhen Salubris Pharmaceuticals in collaboration with Chongqing Fochon Pharmaceutical. It is indicated for the treatment of type 2 diabetes mellitus to improve glycemic control. By inhibiting the DPP-4 enzyme, fotagliptin prevents the rapid degradation of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This action leads to increased insulin secretion and decreased glucagon levels in a glucose-dependent manner, thereby lowering blood glucose levels with a low risk of hypoglycemia and minimal weight gain. Fotagliptin was approved by China's National Medical Products Administration (NMPA) in June 2024.

Brand names: Xindingan
Other names: fotagliptin benzoate

Targets

DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on fotagliptin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fotagliptin.

Explore the full profile